Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163 - Concepedia

Concepedia

Publication | Closed Access

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

260

Citations

21

References

2009

Year

Susan Ellard, Mark Clemons, Karen A. Gelmon, B. Norris, Hagen F. Kennecke, Stephen Chia, Kathleen I. Pritchard, Andrea Eisen, Ted Vandenberg, Marianne Taylor,

Journal of Clinical Oncology

Abstract

Oral everolimus has activity in metastatic breast cancer that is schedule dependent. Daily therapy with 10 mg is worthy of further study in this patient population.

References

	Year	Citations

Page 1